Tag: Small cell lung cancer

Approved by the FDA in 1997, etoposide phosphate is a water-soluble prodrug of the chemotherapy agent etoposide, used to treat specific cancers. It offers key advantages, such as more rapid intravenous infusion and a lower risk of certain side effects, influencing clinical decisions on when to use etoposide phosphate.

In May 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the immunotherapy **AMG 757**, now known as tarlatamab, for treating extensive-stage small cell lung cancer (SCLC). This approval marked a significant milestone, as treatment options for SCLC that has relapsed after initial chemotherapy have historically been limited.

A single 4 mg vial of Zepzelca has a list price of around $8,066.50 in the US, but the total treatment cost depends on several factors. Navigating the expense of this medication, particularly when considering the question of how much is Zepzelca in the US, requires a deep understanding of the variables that influence pricing.

Approved by the FDA in February 2021, trilaciclib is a novel drug for cancer care. So, **what type of drug is trilaciclib?** It is the first-in-class myeloprotection agent, designed to decrease the incidence of chemotherapy-induced bone marrow suppression.

Etoposide, the active ingredient in what may be referred to as Etop Mega Cap, is a cornerstone chemotherapy drug used in combination with other agents to treat cancers like small cell lung cancer and testicular cancer. It belongs to a class of medications called topoisomerase inhibitors.